Searchable abstracts of presentations at key conferences in endocrinology

ea0094p130 | Thyroid | SFEBES2023

Radioactive iodine treatment outcomes at imperial college healthcare NHS Trust

Gnanananthan Pairavi , Papadopoulou Deborah , Khan Sairah , Naik Mitesh , Meeran Karim

Background: Before radioiodine (RAI) therapy patients undergo a technetium 99m thyroid uptake scan and anti-thyroid medication is stopped prior to treatment following clinical review with the nuclear medicine team. Once treated, patients are followed up in the post-radioiodine telephone clinic. Thyroid function is checked at 3, 6, 9 and 12 weeks. Levothyroxine is started once the fT4 is <14 pmol/l.Purpose: To assess ...

ea0096oc2 | Section | UKINETS2023

Interim analysis of Lantana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours (NCT05178693)

Rzeniewicz Karolina , Ward Caroline , Khan Sairah , Naik Mitesh , Barwick Tara , Aboayge Eric , Sharma Rohini

Background: Peptide-receptor-radionuclide-therapy (PRRT) improves progression free survival in metastatic neuroendocrine neoplasia (NEN). To be suitable for PRRT, somatostatin receptor-2 (SSTR2) must be present on tumour site as determined by positive uptake on [68Ga]Ga-DOTA-peptide-PET/CT. LANTana is an ongoing study evaluating whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2, as determined by [68Ga]Ga-DOTA-peptide-PE...